262862-97-5

Basic information

• Product Name: 4-(PHENOXYMETHYL)PHENYL]METHANOL
• Synonyms: 4-(PHENOXYMETHYL)PHENYL]METHANOL
• CAS NO: 262862-97-5
• Molecular Formula: C₁₄H₁₄O₂
• Molecular Weight: 214.263
• Mol File: 262862-97-5.mol

Chemical Properties

• Melting Point: 106 °C
• Boiling Point: 215-220 °C(Press: 13 Torr)
• Appearance: /
• Density: 1.139±0.06 g/cm3(Predicted)
• PKA: 14.34±0.10(Predicted)
• CAS DataBase Reference: 4-(PHENOXYMETHYL)PHENYL]METHANOL(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(PHENOXYMETHYL)PHENYL]METHANOL(262862-97-5)
• EPA Substance Registry System: 4-(PHENOXYMETHYL)PHENYL]METHANOL(262862-97-5)

Safety Data

• Hazardous Substances Data: 262862-97-5(Hazardous Substances Data)

Upstream product

• 16473-35-1 4-(hydroxymethyl)benzyl chloride 
• 108-95-2 phenol 
• 31719-76-3 4-phenoxymethyl-benzoic acid 
• 2683-70-7 4-(phenoxymethyl)benzaldehyde 
• 262288-18-6 4-acetylthio-1-(4-benzylbenzyl)pyrrolidin-2-one 
• 124397-37-1 methyl 4-(phenoxymethyl)benzoate 

Downstream Products

• 34905-00-5 4-phenoxymethylbenzyl chloride 

Relevant articles and documents

Synthesis and in vitro antibacterial activity of gemifloxacin derivatives containing a substituted benzyloxime moiety

A series of novel gemifloxacin (GMFX) derivatives containing a substituted benzyloxime moiety with remarkable improvement in lipophilicity were synthesized. The target compounds evaluated for their in vitro antibacterial activity against representative strains. Our results reveal that most of the target compounds have considerable potency against all of the tested Gram-positive strains including MRSA and MRSE (MIC: 90: 1 μg/mL) is 8-fold more active than GMFX, and 2-fold more active than GMFX and moxifloxacin against MRSE clinical isolates (MIC90: 4 μg/mL). Crown Copyright

CARBOXAMIDES DERIVATIVES

The present invention relates to carboxamides which are useful as an active ingredient of pharmaceutical preparations. The carboxamides of the present invention have IP receptor antagonistic activity, and can be used for the prophylaxis and treatment of diseases associated with IP receptor antagonistic activity.Such diseases include urological diseases or disorder as follows: bladder outlet obstruction, overactive bladder, urinary incontinence, detrusor hyper-reflexia, detrusor instability, reduced bladder capacity, frequency of micturition, urge incontinence, stress incontinence, bladder hyperreactivity, benighn prostatic hypertrophy (BPH), prostatitis, urinary frequency, nocturia, urinary urgency, pelvic hypersensitivity, urethritis, pelvic pain syndrome, prostatodynia, cystitis, or idiophatic bladder hypersensitivity.The compounds of the present invention are also useful for treatment of pain including, but not limited to inflammatory pain, neuropathic pain, acute pain, chronic pain, dental pain, premenstrual pain, visceral pain, headaches, and the like; hypotension;hemophilia and hemorrhage; and inflammation, since the diseases are alleviated by treatment with an IP receptor antagonist.

Thiol compounds, their production and use

Compounds represented by general formula (1) or salts thereof which have a matrix metalloprotease inhibitory activity and are useful as drugs, wherein the rings A and B represent each an optionally substituted homocycle or heterocycle, etc.; R1s are the same or different and each represents hydrogen, optionally substituted hydrocarbyl, acyl, etc.; X1represents a bond, optionally substituted divalent aliphatic hydrocarbyl, etc.; X2represents a bond, optionally substituted divalent aliphatic hydrocarbyl, —O—, etc.; Ys are the same or different represents hydrogen, optionally substituted hydrocarbyl, oxo, etc.; m is 0 or 1; n is an integer of 1 to 3; q1is an integer of 1 to 2n+4; and q2is an integer of 0 to 2n+3, provided that q1+q2is 2n+4.

Carboxylic acid derivatives as IP antagonists

This invention relates to compounds which are generally IP receptor antagonists and which are represented by Formula I: wherein: R1, R2, and R3 are each independently in each occurrence aryl or heteroaryl; R4 is